Prostate Cancer | Specialty

Factors Identified for Improved Survival With Radium-223

November 13th 2015

Researchers are starting to understand which patients with castration-resistant prostate cancer (CRPC) may benefit most from treatment with radium-223.

Use of Radium-223 Continues to Evolve in mCRPC

November 12th 2015

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

Dr. Koo Discusses Focal Therapy for Prostate Cancer

November 10th 2015

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

November 10th 2015

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal

November 7th 2015

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Physicians on the Offense: Get Organized to Thrive in This Payment Arena

November 7th 2015

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

Deliver Androgen Blockade at Prostate Cancer Cells to Achieve Castrate Levels

November 6th 2015

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

Dr. Concepcion Discusses Healthcare's Transition Away From Fee-For-Service

November 6th 2015

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

Novel Combinations Hold Promise in Treatment-Resistant mCRPC

November 6th 2015

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

Crawford Questions ADT Standards, Approaches in Prostate Cancer

November 6th 2015

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

Olaparib Demonstrates High Response in mCRPC With DNA-Repair Defects

November 2nd 2015

The PARP inhibitor olaparib had an overall response rate of nearly 90% in a biomarker-defined subgroup of patients with metastatic castration-resistant prostate cancer who had DNA-repair defects.

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

October 30th 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Sartor Discusses Expanded Radium-223 Program, STAMPEDE Data in Prostate Cancer

October 27th 2015

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

Dr. Saad on Next Steps for Radium-223 in mCRPC

October 26th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.

Combining Radiotherapy With Anti-Androgen Improves Prostate Cancer Survival

October 24th 2015

The additon of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial.

Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More

October 23rd 2015

Prostate Cancer: Every Action Has a Reaction

October 14th 2015

For those who think that men can’t die of prostate cancer, they can spend the day with me in clinic and meet some of the bravest men on the planet who are in the fight of their lives and are unfortunately afflicted with advanced metastatic prostate cancer.

High-Intensity Ultrasound Device for Prostate Surgery Clears FDA Hurdle

October 13th 2015

The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.

Dr. Maha Hussain on Novel Approaches in Prostate Cancer

October 8th 2015

Dr. Poortmans on Impact of Multidisciplinary Approach on Side Effect Management

October 7th 2015

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.